ClinicalTrials.gg
WithdrawnNCT05941273Updated May 18, 2026

A Study of the SING IMT in an Israeli Cohort

An interventional study of smaller incision, new generation implantable miniature telescope (SING-IMT) in Age-Related Macular Degeneration and Geographic Atrophy, sponsored by VisionCare, Inc.. Withdrawn. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2026-05-18.

Primary conditionGeographic AtrophyRegistry: Macular DegenerationReclassifiedWhy we changed it
Registry
Macular Degeneration — the first condition term the registry derived for this study.
ClinicalTrials.gg
Geographic Atrophy
Why
  1. The study's listed conditions name Geographic Atrophy, a narrower term within Macular Degeneration.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by VisionCare, Inc. · Not applicable, Interventional, and Treatment

How we know

Why this study was withdrawn
This decision is driven by the sponsor's strategic considerations.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
55 Years and older
Sex
All
01

Study summary

The objective of this single center study is to determine the safety of the smaller incision, new generation (SING), implantable miniature telescope (IMT) in a small sample of patients with moderate-severe central vision loss due to late-stage age-related macular degeneration (AMD) in an Israeli Cohort

Read the detailed description

The SING IMT has CE Mark in the EU and has been implanted in over 200 patients globally including a pivotal study in the U.S. currently underway (the Concerto Study) and a post-marketing study in EU (The PMCF Study). Model SING is a new injectable model based on the IMT parent model (PMA P050034). Following completion of informed consent, patients will be evaluated for eligibility to enroll into the study, including assessment of their best-corrected distance- and near- visual acuity with refraction, and also when using an external telescope simulator to determine if they are likely to benefit from receiving the SING IMT. If eligible, they will be scheduled for out-patient surgery to implant the IMT during routine cataract surgery in one eye. Following implantation, patients will return for 5 post-operative follow-up visits over a period of approximately 12 months. Additionally, patients will have up to 10 rehabilitation/training visits with a low vision specialist to learn how to use the fellow eye for ambulation and the eye with the implant for magnified viewing during daily activities.

02

Conditions studied

  • Age-Related Macular Degeneration
  • Geographic Atrophy

Browse trials for

Keywords

  • Implantable Miniature Telescope
03

In context

Geographic Atrophy Reclassified

188 studies on the registry are indexed under Geographic Atrophy; 52 are open to participants now.

Browse Geographic Atrophy studies →

Lead sponsor

VisionCare, Inc. is the lead sponsor of 11 studies on the registry; 3 are open to participants now.

Compared within Geographic Atrophy, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Macular Degeneration. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
55 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For Both Eyes:

  • Be at least 55 years of age at the Pre-operative Visit;
  • Have ETDRS BCDVA 0.6 to 1.6 logMAR (20/80 to 20/800) at the Pre-operative Visit;
  • Have bilateral retinal findings of geographic atrophy or disciform scar with foveal involvement, as determined by fluorescein angiography (FA) or OCT;
  • Have an Endothelial Cell Density (ECD) above 1800 cells per millimeter;
  • Have central anterior chamber depth (ACD) >2.5 mm from the posterior surface of the cornea (endothelium) to the anterior surface of the crystalline lens at the Pre-operative Visit;
  • Agree to participate in post-operative visual training

For the Implanted Eye:

  • Have evidence of visually significant cataract at the Pre-operative Visit;
  • Agree to undergo pre-operative assessment with low vision specialists (optometrist, occupational therapist or other professional with low vision experience) in the use of an external telescope model sufficient for patient assessment and patient must achieve at least a 5-letter ETDRS BCDVA improvement (0.1 logMAR) in the final assessment

For the Non-Implanted Eye:

-Have adequate peripheral vision at the Pre-operative Visit to allow navigation.

Exclusion criteria

Exclusion Criteria:

For Both Eyes:

  • Have cognitive impairment that would interfere with the ability to understand and provide or prevent proper visual training/rehabilitation with the device;
  • Have evidence of bilateral active choroidal neovascularization (CNV) on fluorescein angiography or OCT or were treated for CNV within the past six months.
  • Have any of the following conditions at the Pre-operative Visit:

    1. Stargardt macular dystrophy;
    2. Diabetic retinopathy;
    3. Untreated retinal tears;
    4. Retinal vascular disease;
    5. Optic nerve disease;
    6. History of retinal detachment;
    7. Intraocular tumor;
    8. Retinitis pigmentosa;
    9. History of -induced rise in intraocular pressure (IOP), uncontrolled glaucoma, or IOP >22 mmHg at the Pre-operative Visit;
  • Have known allergy to post-operative medications;
  • History of eye rubbing or an ocular condition that predisposes subject to eye rubbing;
  • Have had prior or expected ophthalmic surgery within 30 days of the Operative Visit;
  • Have any circumstance that, based on the Investigator's judgment, poses a concern for the subject's safety;
  • Any systemic disease or clinical evidence of any condition at the Pre-operative Visit which would make the subject in the opinion of the investigator unsuitable for the study;
  • Concurrent participation or prior participation in any investigative drug or device study within last 30 days prior to Pre-operative Visit.

For the Implanted Eye:

  • Have a history of corneal stromal or endothelial dystrophies, including guttata;
  • Have Myopia > 6.0 D or Hyperopia > 4.0 D by Manifest Refraction at the Pre-operative Visit;
  • Have an Axial Length (AL) \< 21 mm at the Pre-operative Visit;
  • Have a narrow angle defined as \< grade 2 on the Schaffer scale at the Pre-operative Visit;
  • Ongoing Inflammatory ocular disease at the Pre-operative Visit;
  • Zonular weakness/instability of crystalline lens, or pseudoexfoliation at the Pre-operative Visit;
  • Have any condition at the Pre-operative Visit which in the judgement of the Investigator indicates that the haptics cannot be placed within the capsular bag during surgery;
  • Have had previous intraocular or corneal surgery, including any type of surgery for refractive or therapeutic purposes;

For the Non-Implanted Eye:

-Have ophthalmic pathology at the Pre-operative Visit that compromises the patient's peripheral vision based on the Investigator's judgment.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Implanted Eye with SING IMT

    The SING IMT is implanted in on eye and safety endpoints are aimed at following that eye over time post-implant

    Device: smaller incision, new generation implantable miniature telescope (SING-IMT)

Interventions

  • Devicesmaller incision, new generation implantable miniature telescope (SING-IMT)

    The IMT (model SING) is an intraocular implant comprised of 2 micro lenses in a glass tube (optics) in a flexible silicone carrier (haptics)

06

What researchers measure

Primary outcomes

  1. Safety: Endothelial cell density

    Percent change in endothelial cell density (ECD) from Pre-operative Visit in study

    Time frame: Comparison of baseline to Visit 5 (330 to 420 days post-operatively)

Secondary outcomes

  1. Adverse Events

    Rates of adverse events from Operative Visit through Visit 5

    Time frame: Approximately 12-months post-operatively (330-420 days)

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jul 2023; primary completion for Jan 2024, 6 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2023
First posted
Jul 12, 2023
StartEst.
Jul 30, 2023
Primary completionEst.
Jan 30, 2024
CompletionActual
Feb 5, 2026
Last update
May 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05941273
Lead sponsor
VisionCare, Inc.
Responsible party
Sponsor
First posted
Jul 12, 2023
Start date
Jul 30, 2023 (estimated)
Primary completion
Jan 30, 2024 (estimated)
Completion
Feb 5, 2026
Last update
May 18, 2026

Study contacts

Guy Kleinman, MD
principal investigator · Wolfson Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion